Health Trials

A Study of 177Lu-PSMA-617 in People With Gliomas

ConditionsGliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-AlteredDiffuse Hemispheric Glioma, H3 G34-mutantDiffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

Eligibility criteria

Qualifiers

Diffuse astrocytoma, IDH-wildtype (grade 2-4)

Glioblastoma, IDH-wildtype

Diffuse midline glioma, H3 K27-altered

Diffuse hemispheric glioma, H3 G34-mutant

Disqualifiers

Patient known to harbor any other non-canonical IDH mutations (i.e., non-R132H)

Target lesion within 5 mm of either the brainstem, optic chiasm or optic nerves Receipt of bevacizumab as part of the initial treatment for glioma

Life expectancy less than 12 weeks

Nonhealing wound, ulcer or bone fracture

Trial design

Treatments tested in this trial

  • Temozolomide
  • 177Lu-PSMA-617
  • 68Ga-PSMA-PET scan/ MRI
  • Quality of Life Questionnaires

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Novartis Pharmaceuticals

Collaborator

Source ClinicalTrials.gov